Frank G Keller1, Sharon M Castellino1, Lu Chen2, Qinglin Pei3, Stephan D Voss4, Kathleen M McCarten5, Stacy L Senn1, Allen B Buxton3, Rizvan Bush3, Louis S Constine6, Cindy L Schwartz7. 1. Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta and Emory University, Atlanta, Georgia. 2. Department of Information Sciences, City of Hope, Duarte, California. 3. Statistics and Data Center, Children's Oncology Group, University of Florida, Gainesville, Florida. 4. Department of Radiology, Boston Children's Hospital, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts. 5. Department of Diagnostic Imaging, Brown University Alpert Medical School, Providence, Rhode Island. 6. Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York. 7. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.
Abstract
BACKGROUND: The Children's Oncology Group AHOD0431 study evaluated a response-directed treatment paradigm in which minimal initial chemotherapy and low-dose radiation was received only by patients who did not achieve a complete remission, and a chemotherapy/low-dose radiation salvage regimen was received by those who had a protocol-defined, low-risk recurrence. METHODS: Patients younger than 21 years who had stage IA or IIA nonbulky disease were eligible. The treatment strategy was evaluated by determining the proportion that received minimal chemotherapy alone, the proportion that had a first or second remission without the receipt of high-dose chemotherapy/stem cell rescue or higher dose involved-field radiation therapy (>21 grays), and overall survival. RESULTS: In total, 278 patients were eligible. At 4 years, 49.0% had received minimal chemotherapy and no radiation, 88.8% were in remission without receiving high-dose chemotherapy with stem cell rescue or >21 grays of involved-field radiation therapy, and the overall survival rate was 99.6%. Patients who had mixed cellularity histology had a 4-year event-free survival (EFS) rate of 95.2%, which was significantly better than the 75.8% EFS for those who had nodular sclerosis histology (P = .008). A red blood cell sedimentation rate ≤20 mm/hour and a negative fluorodeoxyglucose-positron emission tomography scan after 1 cycle of chemotherapy (PET1) were associated with a favorable EFS outcome. The study was closed early when the receipt of radiation therapy exceeded the predefined monitoring boundary. CONCLUSIONS: This limited chemotherapy response-based approach was successful in patients who had a negative PET1 result, had MC histology, or had a low red blood cell sedimentation rate. In this treatment paradigm, evaluation of increased chemotherapy intensity or the integration of active new agents is indicated for patients who have nodular sclerosis histology with a high ESR or who have a positive PET1 result. Cancer 2018.
BACKGROUND: The Children's Oncology Group AHOD0431 study evaluated a response-directed treatment paradigm in which minimal initial chemotherapy and low-dose radiation was received only by patients who did not achieve a complete remission, and a chemotherapy/low-dose radiation salvage regimen was received by those who had a protocol-defined, low-risk recurrence. METHODS:Patients younger than 21 years who had stage IA or IIA nonbulky disease were eligible. The treatment strategy was evaluated by determining the proportion that received minimal chemotherapy alone, the proportion that had a first or second remission without the receipt of high-dose chemotherapy/stem cell rescue or higher dose involved-field radiation therapy (>21 grays), and overall survival. RESULTS: In total, 278 patients were eligible. At 4 years, 49.0% had received minimal chemotherapy and no radiation, 88.8% were in remission without receiving high-dose chemotherapy with stem cell rescue or >21 grays of involved-field radiation therapy, and the overall survival rate was 99.6%. Patients who had mixed cellularity histology had a 4-year event-free survival (EFS) rate of 95.2%, which was significantly better than the 75.8% EFS for those who had nodular sclerosis histology (P = .008). A red blood cell sedimentation rate ≤20 mm/hour and a negative fluorodeoxyglucose-positron emission tomography scan after 1 cycle of chemotherapy (PET1) were associated with a favorable EFS outcome. The study was closed early when the receipt of radiation therapy exceeded the predefined monitoring boundary. CONCLUSIONS: This limited chemotherapy response-based approach was successful in patients who had a negative PET1 result, had MC histology, or had a low red blood cell sedimentation rate. In this treatment paradigm, evaluation of increased chemotherapy intensity or the integration of active new agents is indicated for patients who have nodular sclerosis histology with a high ESR or who have a positive PET1 result. Cancer 2018.
Authors: Monika L Metzger; Howard J Weinstein; Melissa M Hudson; Amy L Billett; Eric C Larsen; Alison Friedmann; Scott C Howard; Sarah S Donaldson; Matthew J Krasin; Larry E Kun; Karen J Marcus; Torunn I Yock; Nancy Tarbell; Catherine A Billups; Jianrong Wu; Michael P Link Journal: JAMA Date: 2012-06-27 Impact factor: 56.272
Authors: Paul D Harker-Murray; Richard A Drachtman; David C Hodgson; Allen Russell Chauvenet; Kara M Kelly; Peter David Cole Journal: Pediatr Blood Cancer Date: 2013-11-08 Impact factor: 3.167
Authors: Debra L Friedman; Lu Chen; Suzanne Wolden; Allen Buxton; Kathleen McCarten; Thomas J FitzGerald; Sandra Kessel; Pedro A De Alarcon; Allen R Chen; Nathan Kobrinsky; Peter Ehrlich; Robert E Hutchison; Louis S Constine; Cindy L Schwartz Journal: J Clin Oncol Date: 2014-10-13 Impact factor: 44.544
Authors: Sarah S Donaldson; Michael P Link; Howard J Weinstein; Shesh N Rai; Sam Brain; Amy L Billett; Craig A Hurwitz; Matthew Krasin; Larry E Kun; Karen C Marcus; Nancy J Tarbell; Jeffrey A Young; Melissa M Hudson Journal: J Clin Oncol Date: 2007-01-20 Impact factor: 44.544
Authors: Maureen M O'Brien; Sarah S Donaldson; Raymond R Balise; Alice S Whittemore; Michael P Link Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Wolfgang Dörffel; Ursula Rühl; Heike Lüders; Alexander Claviez; Marion Albrecht; Jos Bökkerink; Harald Holte; Jonas Karlen; Georg Mann; Heinz Marciniak; Felix Niggli; Kjeld Schmiegelow; Ernst-Wilhelm Schwarze; Richard Pötter; Lutz Wickmann; Günther Schellong Journal: J Clin Oncol Date: 2013-03-18 Impact factor: 44.544
Authors: Andrea Gallamini; Martin Hutchings; Luigi Rigacci; Lena Specht; Francesco Merli; Mads Hansen; Caterina Patti; Annika Loft; Francesco Di Raimondo; Francesco D'Amore; Alberto Biggi; Umberto Vitolo; Caterina Stelitano; Rosario Sancetta; Livio Trentin; Stefano Luminari; Emilio Iannitto; Simonetta Viviani; Ivana Pierri; Alessandro Levis Journal: J Clin Oncol Date: 2007-07-23 Impact factor: 44.544
Authors: Daniel M Green; Vikki G Nolan; Pamela J Goodman; John A Whitton; DeoKumar Srivastava; Wendy M Leisenring; Joseph P Neglia; Charles A Sklar; Sue C Kaste; Melissa M Hudson; Lisa R Diller; Marilyn Stovall; Sarah S Donaldson; Leslie L Robison Journal: Pediatr Blood Cancer Date: 2013-08-12 Impact factor: 3.167
Authors: Justine M Kahn; Kara M Kelly; Qinglin Pei; Rizvan Bush; Debra L Friedman; Frank G Keller; Smita Bhatia; Tara O Henderson; Cindy L Schwartz; Sharon M Castellino Journal: J Clin Oncol Date: 2019-09-20 Impact factor: 44.544
Authors: Justine M Kahn; Qinglin Pei; Debra L Friedman; Joel Kaplan; Frank G Keller; David Hodgson; Yue Wu; Burton E Appel; Smita Bhatia; Tara O Henderson; Cindy L Schwartz; Kara M Kelly; Sharon M Castellino Journal: Lancet Haematol Date: 2022-01 Impact factor: 18.959
Authors: Katie A Greenzang; Hasan Al-Sayegh; Clement Ma; Mehdi Najafzadeh; Eve Wittenberg; Jennifer W Mack Journal: Pediatrics Date: 2020-04-13 Impact factor: 7.124
Authors: Kevin C Oeffinger; Kayla L Stratton; Melissa M Hudson; Wendy M Leisenring; Tara O Henderson; Rebecca M Howell; Suzanne L Wolden; Louis S Constine; Lisa R Diller; Charles A Sklar; Paul C Nathan; Sharon M Castellino; Dana Barnea; Susan A Smith; Raymond J Hutchinson; Gregory T Armstrong; Leslie L Robison Journal: J Clin Oncol Date: 2021-02-25 Impact factor: 50.717
Authors: James E Bates; Stephanie Terezakis; Christopher G Morris; Avani D Rao; Shuchi Sehgal; Rahul Kumar; Raymond B Mailhot Vega; Nancy P Mendenhall; Bradford S Hoppe Journal: Int J Part Ther Date: 2021-07-08
Authors: Matthew D Hall; Stephanie A Terezakis; John T Lucas; Eve Gallop-Evans; Karin Dieckmann; Louis S Constine; David Hodgson; Jamie E Flerlage; Monika L Metzger; Bradford S Hoppe Journal: Int J Radiat Oncol Biol Phys Date: 2021-08-12 Impact factor: 7.038
Authors: Sachin R Jhawar; Zorimar Rivera-Núñez; Richard Drachtman; Peter D Cole; Bradford S Hoppe; Rahul R Parikh Journal: JAMA Oncol Date: 2019-05-01 Impact factor: 31.777
Authors: Sarah A Milgrom; Jihyun Kim; Alin Chirindel; Jongho Kim; Qinglin Pei; Lu Chen; Allen Buxton; Sandy Kessel; Jeffrey Leal; Kathleen M McCarten; Bradford S Hoppe; Suzanne L Wolden; Cindy L Schwartz; Debra L Friedman; Kara M Kelly; Steve Y Cho Journal: Pediatr Blood Cancer Date: 2021-07-10 Impact factor: 3.838